ImmunityBio financials
$8.83+3.64%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $51.2M | $44.2M | $38.3M | $32.1M | $26.4M | $16.5M | $7.6M | $6.1M | $1.0M | $40.0K | $139.0K | $82.0K |
| Gross profit | $50.9M | $44.0M | $37.9M | $31.9M | $26.3M | $16.5M | $7.6M | $6.1M | $1.0M | $40.0K | $139.0K | $82.0K |
| Gross margin | 99.4% | 99.5% | 99.0% | 99.4% | 99.5% | 99.6% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$61.7M | -$69.8M | -$64.7M | -$55.6M | -$71.3M | -$64.4M | -$69.4M | -$80.3M | -$99.3M | -$95.2M | -$85.4M | -$80.1M |
| Net income | -$230.4M | -$632.8M | -$61.9M | -$67.3M | -$92.6M | -$129.6M | -$59.2M | -$85.7M | -$134.6M | -$134.1M | -$233.4M | -$95.6M |
| Net margin | −449.6% | −1431.4% | −161.8% | −209.8% | −350.3% | −784.9% | −783.4% | −1404.0% | −12852.3% | −335272.5% | −167907.9% | −116563.4% |
| Diluted EPS | $-0.22 | $-0.62 | $-0.06 | $-0.07 | $-0.10 | $-0.15 | $-0.08 | $-0.14 | $-0.20 | $-0.20 | $-0.35 | $-0.19 |
| EBITDA | -$57.3M | -$65.4M | -$60.8M | -$51.7M | -$67.4M | -$60.6M | -$65.3M | -$75.8M | -$94.9M | -$90.6M | -$84.5M | -$75.6M |
| Operating cash flow | -$66.5M | -$75.4M | -$70.4M | -$68.9M | -$79.7M | -$85.9M | -$85.1M | -$98.8M | -$100.3M | -$107.0M | -$115.3M | -$87.4M |
| Free cash flow | -$70.0M | -$77.1M | -$71.3M | -$69.6M | -$80.8M | -$87.0M | -$87.3M | -$101.6M | -$101.1M | -$108.2M | -$123.2M | -$93.1M |
| Diluted shares | 1,050.1M | 1,026.9M | 991.5M | 946.6M | 888.2M | 853.2M | 744.0M | 698.0M | 686.9M | 672.8M | 670.3M | 498.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $75.7M | $205.2M | $88.3M | $60.2M | $137.7M | $60.7M |
| Short-term investments | $281.7M | $175.7M | $154.5M | $197.6M | $16.0M | $931.0K |
| Total debt | $415.1M | $404.3M | $324.6M | $316.1M | $307.0M | $296.3M |
| Total assets | $628.5M | $646.6M | $501.9M | $519.0M | $402.1M | $303.8M |
| Total liabilities | $1.67B | $1.52B | $1.00B | $1.04B | $971.9M | $894.2M |
| Shareholders' equity | -$1.05B | -$869.1M | -$499.6M | -$523.4M | -$569.8M | -$590.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology